CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...